Tech Brainiacs!

Looking around, all what you see is technology developing from one minute to another. Who is behind these developments? Who are the brains behind some of the most intellectual technology?? Here are three names you can think off, while answering these questions..

Steve Jobs
CEO, Apple

When Steve Jobs returned to Apple in 1997 after a 12-year exile, the company was close to bankruptcy. Thirteen years later it has a market cap of $250 billion and is the world’s most valuable tech company, transforming whole industries along the way. iTunes reinvented music. Pixar, now part of Disney, elevated animated films. The iPhone changed telecom. And the new iPad has other computer makers scrambling to respond. Rocking one industry could be luck, but upending four? That’s smart. He is a visionary, a micromanager, and a showman who creates such anticipation around new products that their releases are veritable holidays.

Jeff Bezos
CEO Amazon.com

Jeff Bezos never stops innovating. Bezos launched Amazon as an online bookstore in 1994, then turned it into a massive virtual mall open to other vendors’ wares. Now he’s done the same with Amazon’s cloud computing services, which let customers rent data storage and computing power from Amazon. Then there’s the Kindle, which has helped redefine the very concept of the book. Though the company hasn’t disclosed the number of Kindle users, its eBook selection has grown tenfold to 600,000. And while the iPad is getting all the eReader love these days, Bezos got there first, and virtually every iPad review compares Steve Jobs’ tablet to Bezos’ device.

Mitch Gold

CEO Dendreon

For the 192,000 men diagnosed with prostate cancer last year, Dr. Mitch Gold’s Seattle-based BioTech company Dendreon may hold the key to their survival. The Food and Drug Administration last April finally approved Provenge, a prostate cancer vaccine that stimulates the body’s own immune system to attack tumors. In one clinical trial, Provenge extended the lives of patients with prostate cancer on average by 4.1 months, with 32% of patients still alive three years after treatment. While Gold and Dendreon stand to benefit — it’s estimated Provenge could generate more than $1 billion in U.S. sales — ultimately the real beneficiaries will be the patients themselves